Drug intelligence / Profile preview

benzilone

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Benzilone (also known as benzilonium) is an antimuscarinic and antispasmodic drug. It acts as a quaternary ammonium compound with minimal passage across the blood-brain barrier, resulting in limited central nervous system effects. Benzilone is used to treat gastrointestinal disorders and has been investigated for its potential in managing respiratory issues due to its anticholinergic properties[3][4][5]. The drug has reached clinical trial phase II for at least one indication.

Other names: benziloniumbenzilonium ionbenzilonium cationUNII-GY56LQX77BUNII-GY-56LQX77BUNII-GY 56LQX77B

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on benzilone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on benzilone.

Explore the full profile